Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Savara Inc.

< Previous 1 2 3 Next >
Savara Reports First Quarter Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Leadership Appointments
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Third Quarter 2022 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Participate in Three Upcoming Investor Conferences
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Resignation of Chief Medical Officer
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Second Quarter 2022 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at Jefferies Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at H.C. Wainwright Global Investment Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports First Quarter 2022 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Participate in Two Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Third Quarter 2021 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.